H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. NVDA
6. WMT
7. SPY
8. RXST
9. RIVN
10. LMT

Go back to H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

August 12, 2024 8:00 AM EDT

Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024

Dosing Initiated in ARCHER II Registrational Trial for ANX007; Only Program to Demonstrate Significant Vision Protection and Structural Protection in Regions of the Eye Important for Vision Acuity in GA; Phase 3 Data Expected Second Half 2026

First-in-Kind Oral C1s Inhibitor ANX1502 Successfully Completed Bridging Study to Twice-Daily Tablet; Proof-of-Concept Data in Autoimmune Disease Expected... More